| Primary |
| Prophylaxis |
13.8% |
| Aspergillosis |
10.6% |
| Pneumocystis Jirovecii Pneumonia |
10.6% |
| Bronchopulmonary Aspergillosis |
9.6% |
| Candidiasis |
5.3% |
| Pyrexia |
5.3% |
| Acute Myeloid Leukaemia |
4.3% |
| B Precursor Type Acute Leukaemia |
4.3% |
| Febrile Neutropenia |
4.3% |
| Acute Lymphocytic Leukaemia |
3.2% |
| Aspergillus Infection |
3.2% |
| Bone Marrow Conditioning Regimen |
3.2% |
| Bronchopneumonia |
3.2% |
| Cytomegalovirus Infection |
3.2% |
| Mineral Supplementation |
3.2% |
| Sepsis |
3.2% |
| Vitamin Supplementation |
3.2% |
| Candida Sepsis |
2.1% |
| Lung Infection |
2.1% |
| Pneumonia |
2.1% |
|
| Drug Ineffective |
28.2% |
| Pneumonia |
7.7% |
| Convulsion |
5.1% |
| No Therapeutic Response |
5.1% |
| Pyrexia |
5.1% |
| Renal Failure Acute |
5.1% |
| Sepsis |
5.1% |
| Septic Shock |
5.1% |
| Systemic Mycosis |
5.1% |
| Atrioventricular Block |
2.6% |
| Bronchopulmonary Aspergillosis |
2.6% |
| Coma |
2.6% |
| Deafness Bilateral |
2.6% |
| Drug Resistance |
2.6% |
| Fungal Endocarditis |
2.6% |
| Gastric Ulcer |
2.6% |
| Graft Versus Host Disease |
2.6% |
| Hepatic Enzyme Increased |
2.6% |
| Nausea |
2.6% |
| Neutropenia |
2.6% |
|
| Secondary |
| Product Used For Unknown Indication |
30.8% |
| Drug Use For Unknown Indication |
11.8% |
| Acute Myeloid Leukaemia |
6.8% |
| Pain |
5.9% |
| Bronchopulmonary Aspergillosis |
4.6% |
| Pneumocystis Jiroveci Pneumonia |
4.4% |
| Systemic Candida |
4.4% |
| Aspergillosis |
3.5% |
| Infection |
3.5% |
| Myelodysplastic Syndrome |
3.5% |
| Antifungal Treatment |
3.1% |
| Pneumonia |
2.8% |
| Pyrexia |
2.8% |
| Systemic Mycosis |
2.2% |
| T-cell Type Acute Leukaemia |
2.0% |
| Pneumocystis Jirovecii Pneumonia |
1.8% |
| Fungal Infection |
1.7% |
| Candidiasis |
1.5% |
| Ewing's Sarcoma Metastatic |
1.5% |
| Lung Disorder |
1.5% |
|
| Venoocclusive Liver Disease |
29.5% |
| Drug Ineffective |
9.1% |
| Multi-organ Failure |
6.8% |
| Pyrexia |
5.7% |
| Venoocclusive Disease |
5.7% |
| Cerebral Haemorrhage |
3.4% |
| Dilatation Intrahepatic Duct Acquired |
3.4% |
| Liver Function Test Abnormal |
3.4% |
| Neutropenia |
3.4% |
| Respiratory Failure |
3.4% |
| Septic Shock |
3.4% |
| Toxic Epidermal Necrolysis |
3.4% |
| Unresponsive To Stimuli |
3.4% |
| Brain Abscess |
2.3% |
| Hepatic Enzyme Increased |
2.3% |
| Hepatotoxicity |
2.3% |
| Mania |
2.3% |
| Pneumothorax |
2.3% |
| Proteinuria |
2.3% |
| Toxic Skin Eruption |
2.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
47.0% |
| Drug Use For Unknown Indication |
11.6% |
| Pneumonia |
8.1% |
| Acute Myeloid Leukaemia |
5.9% |
| Prophylaxis |
4.2% |
| Systemic Candida |
2.7% |
| Acute Lymphocytic Leukaemia |
2.0% |
| Haemoptysis |
1.9% |
| Hepatic Function Abnormal |
1.9% |
| Leukaemia |
1.9% |
| Infection |
1.8% |
| Febrile Neutropenia |
1.6% |
| Pyrexia |
1.5% |
| Acute Leukaemia |
1.4% |
| Rash |
1.3% |
| Candidiasis |
1.1% |
| Antifungal Prophylaxis |
1.0% |
| Pain |
1.0% |
| Prophylaxis Against Graft Versus Host Disease |
1.0% |
| Sepsis |
1.0% |
|
| Respiratory Failure |
19.8% |
| Disseminated Intravascular Coagulation |
10.3% |
| Vomiting |
10.3% |
| Venoocclusive Disease |
8.6% |
| Pyrexia |
5.2% |
| Sepsis |
4.3% |
| Death |
3.4% |
| Hepatic Failure |
3.4% |
| Infection |
3.4% |
| Lung Disorder |
3.4% |
| Pneumonia |
3.4% |
| Systemic Candida |
3.4% |
| Candida Sepsis |
2.6% |
| Drug Ineffective |
2.6% |
| Febrile Neutropenia |
2.6% |
| Muscular Weakness |
2.6% |
| Myocardial Infarction |
2.6% |
| Overdose |
2.6% |
| Pneumonitis |
2.6% |
| Renal Failure |
2.6% |
|
| Interacting |
| Infection |
36.4% |
| Tuberculosis |
27.3% |
| Immunosuppression |
18.2% |
| Sepsis |
18.2% |
|
| Liver Injury |
50.0% |
| Blood Alkaline Phosphatase Increased |
25.0% |
| Hepatic Failure |
25.0% |
|
